Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

v2.4.1.9
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 14,257us-gaap_CashAndCashEquivalentsAtCarryingValue $ 3,970us-gaap_CashAndCashEquivalentsAtCarryingValue
Accounts receivable 146us-gaap_AccountsReceivableNetCurrent 122us-gaap_AccountsReceivableNetCurrent
Marketable securities 993us-gaap_MarketableSecuritiesCurrent 1,975us-gaap_MarketableSecuritiesCurrent
Prepaid and other current assets 192us-gaap_PrepaidExpenseAndOtherAssetsCurrent 144us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Mortgage note receivable, current portion 166us-gaap_NotesAndLoansReceivableNetCurrent 165us-gaap_NotesAndLoansReceivableNetCurrent
Total current assets 15,754us-gaap_AssetsCurrent 6,376us-gaap_AssetsCurrent
Property and equipment, net 245us-gaap_PropertyPlantAndEquipmentNet 284us-gaap_PropertyPlantAndEquipmentNet
Deposits 31us-gaap_DepositsAssetsNoncurrent 31us-gaap_DepositsAssetsNoncurrent
Mortgage note receivable, long-term portion 2,412us-gaap_NotesAndLoansReceivableNetNoncurrent 2,431us-gaap_NotesAndLoansReceivableNetNoncurrent
In process research and development 184,966us-gaap_DevelopmentInProcess 184,966us-gaap_DevelopmentInProcess
Goodwill 65,195us-gaap_Goodwill 65,195us-gaap_Goodwill
Total assets 268,603us-gaap_Assets 259,283us-gaap_Assets
Current liabilities:    
Accounts payable 737us-gaap_AccountsPayableCurrent 299us-gaap_AccountsPayableCurrent
Accrued expenses 455us-gaap_AccruedLiabilitiesCurrent 394us-gaap_AccruedLiabilitiesCurrent
Derivative liabilities 13,456us-gaap_DerivativeLiabilitiesCurrent 8,464us-gaap_DerivativeLiabilitiesCurrent
Total current liabilities 14,648us-gaap_LiabilitiesCurrent 9,157us-gaap_LiabilitiesCurrent
Long-term liabilities    
Deferred rent 62us-gaap_DeferredRentCreditNoncurrent 62us-gaap_DeferredRentCreditNoncurrent
Deferred tax liability 65,195us-gaap_DeferredTaxLiabilitiesNoncurrent 65,195us-gaap_DeferredTaxLiabilitiesNoncurrent
Total long-term liabilities 65,257us-gaap_LiabilitiesNoncurrent 65,257us-gaap_LiabilitiesNoncurrent
Total liabilities 79,905us-gaap_Liabilities 74,414us-gaap_Liabilities
Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, 0 and 1,000 issued and outstanding at March 31, 2015 and December 31, 2014, issued in the merger with RFS Pharma, LLC    178,218COCP_SeriesAConvertiblePreferredStock
Stockholders' equity:    
Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 0 and 1,000 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively    1COCP_SeriesBConvertiblePreferredStock
Common stock, $.001 par value; 800,000 and 200,000 shares authorized, 687,219 and 122,494 issued and outstanding as of March 31, 2015 and December 31, 2014, respectively 687us-gaap_CommonStockValue 123us-gaap_CommonStockValue
Additional paid-in capital 217,731us-gaap_AdditionalPaidInCapital 18,725us-gaap_AdditionalPaidInCapital
Accumulated other comprehensive income (loss), net of tax (744)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax 236us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax
Accumulated deficit (28,976)us-gaap_RetainedEarningsAccumulatedDeficit (12,434)us-gaap_RetainedEarningsAccumulatedDeficit
Total stockholders' equity 188,698us-gaap_StockholdersEquity 6,651us-gaap_StockholdersEquity
Total liabilities and stockholders' equity $ 268,603us-gaap_LiabilitiesAndStockholdersEquity $ 259,283us-gaap_LiabilitiesAndStockholdersEquity